PENICILLAMINE

Post-LOE

penicillamine

Gen Pharmaceuticals

ANDAORALCAPSULE

Approved

Aug 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

PENICILLAMINE (penicillamine) by Gen Pharmaceuticals is clinical pharmacology penicillamine is a chelating agent recommended for the removal of excess copper in patients with wilson's disease. Approved for the treatment of wilson's disease, cystinuria, active rheumatoid arthritis and 3 more indications. First approved in 2021.

Drug data last refreshed 23h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. From in vitro studies which indicate that one atom of copper combines with two molecules of penicillamine, it would appear that one gram of penicillamine should…

Worked on PENICILLAMINE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

PENICILLAMINE

Mechanism of Action

Indications (5)